NCT05937906View on ClinicalTrials.gov

Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

May 25, 2028

Study Completion Date

May 25, 2028

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Phase I - Mirdametinib - Level 1

Mirdametinib 4 mg twice/day for 7 days per cycle

DRUG

Phase II - Mirdametinib

For phase 2 : Randomisation with 2 arm : Standard arm and experimental arm

DRUG

Phase I - Mirdametinib - Level 2

Mirdametinib 4 mg twice/day for 14 days per cycle

DRUG

Phase I - Mirdametinib - Level 3

Mirdametinib 6 mg twice/day for 7 days per cycle

DRUG

Phase I - Mirdametinib - Level 4

Mirdametinib 6 mg twice/day for 14 days per cycle

Trial Locations (1)

21000

RECRUITING

Centre Georges-François Leclerc, Dijon

All Listed Sponsors
lead

Centre Georges Francois Leclerc

OTHER